//
Yuji Mishima
Jens Lohr
Yu-Tzu Tai
Ludmila Flores
Yosra Aljawai
Jacob P. Laubach
Paul G. Richardson
Aldo M Roccaro
Kenneth C. Anderson
Nikhil C. Munshi
Irene M. Ghobrial
Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Dana-Farber Cancer Institute, Boston, MA
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Womens Hospital, Harvard Medical School, Boston, MA
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Boston, MA
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
United States
N/A
Endocrine/metabolic Diseases (ME)
Hematological malignancies
Primary plasma cell leukemia
Multiple Myeloma
Solid malignancies
Monoclonal gammopathy
Circulating tumor cells
Cluster of Differentiation 19
Cluster of Differentiation 38
Cluster of Differentiation 44
Cluster of differentiation 45
Cluster of Differentiation 56
C-X-C motif chemokine receptor 3
Lymphocyte count
Syndecan-1
White Blood Cell
Monoclonal gammopathy of undetermined significance
N/A
N/A
N/A
NA
N/A
N/A
Interim